REGN-1400

• Target:

  EGFR

• Related Pathways:

  JAK/STAT signaling|||Tyrosine Kinase/Adaptors|||Angiogenesis

• Bioactivity:

  REGN-1400 is a fully human monoclonal antibody inhibitor targeting ErbB3. By inhibiting ErbB3, REGN-1400 blocks associated signaling pathways to reduce tumor cell proliferation. It shows potential for research in solid tumors such as non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and squamous cell carcinoma of the head and neck (SCCHN) .

• Shipping Conditions:

  Cool pack

• Storage Temperature:

  -20°C